Abstract | BACKGROUND AND OBJECTIVES: The dramatically high rates of mortality and cardiovascular morbidity observed among dialysis patients highlights the importance of identifying and implementing strategies to lower cardiovascular risk in this population. Results from clinical trials undertaken thus far, including trials on lipid reduction, normalization of hematocrit, and increased dialysis dosage, have been unsuccessful. Available data indicate that abnormalities in calcium and phosphorus metabolism, as a result of either secondary hyperparathyroidism alone or the therapeutic measures used to manage secondary hyperparathyroidism, are associated with an increased risk for death and cardiovascular events. However, no prospective trials have evaluated whether interventions that modify these laboratory parameters result in a reduction in adverse cardiovascular outcomes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: RESULTS: The study will be event driven (terminated at 1882 events) with an anticipated duration of approximately 4 yr. CONCLUSIONS:
|
Authors | Glenn M Chertow, Lara B Pupim, Geoffrey A Block, Ricardo Correa-Rotter, Tilman B Drueke, Jürgen Floege, William G Goodman, Gerard M London, Kenneth W Mahaffey, Sharon M Moe, David C Wheeler, Moetaz Albizem, Kurt Olson, Preston Klassen, Patrick Parfrey |
Journal | Clinical journal of the American Society of Nephrology : CJASN
(Clin J Am Soc Nephrol)
Vol. 2
Issue 5
Pg. 898-905
(Sep 2007)
ISSN: 1555-905X [Electronic] United States |
PMID | 17702710
(Publication Type: Journal Article)
|
Chemical References |
|
Topics |
- Cardiovascular Diseases
(etiology, prevention & control)
- Cinacalcet
- Double-Blind Method
- Humans
- Hyperparathyroidism, Secondary
(complications, drug therapy)
- Naphthalenes
(therapeutic use)
- Randomized Controlled Trials as Topic
(methods)
- Renal Dialysis
|